NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
Authors:
- Vincenzo QuagliarielloVincenzo Quagliariello
- Michelino De LaurentiisMichelino De Laurentiis
- Stefania CoccoSCStefania Cocco
- Giuseppina ReaGRGiuseppina Rea
- Annamaria BonelliABAnnamaria Bonelli
- Antonietta CaronnaACAntonietta Caronna
- Maria Cristina LombariMLMaria Cristina Lombari
- Gabriele ConfortiGCGabriele Conforti
- Massimiliano BerrettaMassimiliano Berretta
- Gerardo BottiGBGerardo Botti
- Nicola MaureaNMNicola Maurea
Open Access
- 21 October 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (20) , 7802
Abstract
Hyperglycemia, obesity and metabolic syndrome are negative prognostic factors in breast cancer patients. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, achieving unprecedented efficacy in multiple malignancies. However, ICIs are associated with immune-related adverse events involving cardiotoxicity. We aimed to study if hyperglycemia could affect ipilimumab-induced anticancer efficacy and enhance its cardiotoxicity. Human cardiomyocytes and estrogen-responsive and triple-negative breast cancer cells (MCF-7 and MDA-MB-231 cell lines) were exposed to ipilimumab under high glucose (25 mM); low glucose (5.5 mM); high glucose and co-administration of SGLT-2 inhibitor (empagliflozin); shifting from high glucose to low glucose. Study of cell viability and the expression of new putative biomarkers of cardiotoxicity and resistance to ICIs (NLRP3, MyD88, cytokines) were quantified through ELISA (Cayman Chemical) methods. Hyperglycemia during treatment with ipilimumab increased cardiotoxicity and reduced mortality of breast cancer cells in a manner that is sensitive to NLRP3. Notably, treatment with ipilimumab and empagliflozin under high glucose or shifting from high glucose to low glucose reduced significantly the magnitude of the effects, increasing responsiveness to ipilimumab and reducing cardiotoxicity. To our knowledge, this is the first evidence that hyperglycemia exacerbates ipilimumab-induced cardiotoxicity and decreases its anticancer efficacy in MCF-7 and MDA-MB-231 cells. This study sets the stage for further tests on other breast cancer cell lines and primary cardiomyocytes and for preclinical trials in mice aimed to decrease glucose through nutritional interventions or administration of gliflozines during treatment with ipilimumab.Keywords
Funding Information
- Ministero della Salute (“Ricerca Corrente” grant from the Italian Ministry of Health. “Cardiotossicità dei trattamenti antineoplastici: identificazione precoce e strategie di cardioprotezione” Project code: M1/5-C)
This publication has 92 references indexed in Scilit:
- The Effect of Lung Cancer on Cytokine Expression in Peripheral Blood Mononuclear CellsPLOS ONE, 2013
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α productionJournal of Translational Medicine, 2013
- Diabetes and Risk of CancerISRN Oncology, 2013
- Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cellsJournal of Proteomics, 2012
- Interleukin-6 - A Key Regulator of Colorectal Cancer DevelopmentInternational Journal of Biological Sciences, 2012
- MyD88 and Trif Signaling Play Distinct Roles in Cardiac Dysfunction and Mortality during Endotoxin Shock and Polymicrobial SepsisAnesthesiology, 2011
- IL-18 Induces PD-1–Dependent Immunosuppression in CancerCancer Research, 2011
- Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter studyLung Cancer, 2010
- Hyperglycemia-Induced Reactive Oxygen Species Toxicity to Endothelial Cells Is Dependent on Paracrine MediatorsDiabetes, 2008
- Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell linesClinical and Experimental Immunology, 2007